nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—prostate gland—prostate cancer	0.0291	0.192	CbGeAlD
Plerixafor—CXCR4—seminal vesicle—prostate cancer	0.0246	0.162	CbGeAlD
Plerixafor—CXCR4—epithelium—prostate cancer	0.0214	0.141	CbGeAlD
Plerixafor—CXCR4—renal system—prostate cancer	0.0199	0.131	CbGeAlD
Plerixafor—CXCR4—urethra—prostate cancer	0.0195	0.129	CbGeAlD
Plerixafor—CXCR4—bone marrow—prostate cancer	0.015	0.099	CbGeAlD
Plerixafor—CXCR4—testis—prostate cancer	0.0128	0.0846	CbGeAlD
Plerixafor—CXCR4—lymph node—prostate cancer	0.0093	0.0613	CbGeAlD
Plerixafor—CXCR4—Disease—AOX1—prostate cancer	0.000861	0.00275	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GRPR—prostate cancer	0.000852	0.00272	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—ERCC2—prostate cancer	0.000848	0.00271	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—prostate cancer	0.000844	0.0027	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—PTHLH—prostate cancer	0.000783	0.0025	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HSD17B1—prostate cancer	0.000779	0.00249	CbGpPWpGaD
Plerixafor—CXCR4—Disease—DNAJC3—prostate cancer	0.000779	0.00249	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTBP2—prostate cancer	0.000779	0.00249	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—MC2R—prostate cancer	0.00077	0.00246	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	0.000759	0.00242	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—OR51E2—prostate cancer	0.000754	0.00241	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—ANXA1—prostate cancer	0.000736	0.00235	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—WNT4—prostate cancer	0.000733	0.00234	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MC2R—prostate cancer	0.0007	0.00224	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL17RD—prostate cancer	0.000694	0.00222	CbGpPWpGaD
Plerixafor—CXCR4—Disease—B4GALT4—prostate cancer	0.000694	0.00222	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BMPR1B—prostate cancer	0.00069	0.0022	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CALCA—prostate cancer	0.000689	0.0022	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PENK—prostate cancer	0.000687	0.00219	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CXCL12—prostate cancer	0.000673	0.00215	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—prostate cancer	0.000666	0.00213	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—prostate cancer	0.00066	0.00211	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RGS17—prostate cancer	0.000641	0.00205	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PENK—prostate cancer	0.000624	0.00199	CbGpPWpGaD
Plerixafor—CXCR4—Disease—WNT4—prostate cancer	0.000619	0.00198	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GNRH1—prostate cancer	0.000584	0.00187	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—VIP—prostate cancer	0.000584	0.00187	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—ADRB2—prostate cancer	0.000578	0.00185	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RLN2—prostate cancer	0.000572	0.00183	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—LPAR1—prostate cancer	0.000565	0.00181	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GRP—prostate cancer	0.000565	0.00181	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PLCB2—prostate cancer	0.00056	0.00179	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPL12—prostate cancer	0.000555	0.00177	CbGpPWpGaD
Plerixafor—CXCR4—Disease—LDHB—prostate cancer	0.000555	0.00177	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—prostate cancer	0.000546	0.00175	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTBP2—prostate cancer	0.000545	0.00174	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HSD17B1—prostate cancer	0.000545	0.00174	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—prostate cancer	0.000544	0.00174	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PDE4D—prostate cancer	0.000534	0.00171	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GNRH1—prostate cancer	0.00053	0.00169	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—VIP—prostate cancer	0.00053	0.00169	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TCN2—prostate cancer	0.000526	0.00168	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PLXNB1—prostate cancer	0.000523	0.00167	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—LPAR1—prostate cancer	0.000514	0.00164	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GRP—prostate cancer	0.000514	0.00164	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PLCB2—prostate cancer	0.000508	0.00162	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GNG5—prostate cancer	0.000508	0.00162	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GRPR—prostate cancer	0.000503	0.00161	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CX3CL1—prostate cancer	0.000499	0.00159	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL17RD—prostate cancer	0.000486	0.00155	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PDE4D—prostate cancer	0.000485	0.00155	CbGpPWpGaD
Plerixafor—Immune system disorder—Capecitabine—prostate cancer	0.000476	0.000889	CcSEcCtD
Plerixafor—Abdominal pain—Estradiol—prostate cancer	0.000474	0.000886	CcSEcCtD
Plerixafor—Headache—Goserelin—prostate cancer	0.000474	0.000886	CcSEcCtD
Plerixafor—Erythema—Docetaxel—prostate cancer	0.000473	0.000884	CcSEcCtD
Plerixafor—Rash—Conjugated Estrogens—prostate cancer	0.000473	0.000883	CcSEcCtD
Plerixafor—Dermatitis—Conjugated Estrogens—prostate cancer	0.000472	0.000882	CcSEcCtD
Plerixafor—Haemoglobin—Prednisone—prostate cancer	0.000471	0.000881	CcSEcCtD
Plerixafor—Headache—Conjugated Estrogens—prostate cancer	0.00047	0.000877	CcSEcCtD
Plerixafor—Haemorrhage—Prednisone—prostate cancer	0.000469	0.000876	CcSEcCtD
Plerixafor—Anaphylactic shock—Etoposide—prostate cancer	0.000465	0.000869	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—prostate cancer	0.000461	0.000862	CcSEcCtD
Plerixafor—Mental disorder—Capecitabine—prostate cancer	0.000461	0.000862	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—GNG5—prostate cancer	0.000461	0.00147	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Prednisone—prostate cancer	0.000461	0.000861	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—prostate cancer	0.000461	0.00147	CbGpPWpGaD
Plerixafor—Feeling abnormal—Mitoxantrone—prostate cancer	0.000461	0.000861	CcSEcCtD
Plerixafor—Erythema—Capecitabine—prostate cancer	0.000458	0.000856	CcSEcCtD
Plerixafor—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000457	0.000854	CcSEcCtD
Plerixafor—Flatulence—Capecitabine—prostate cancer	0.000452	0.000844	CcSEcCtD
Plerixafor—Skin disorder—Etoposide—prostate cancer	0.000452	0.000844	CcSEcCtD
Plerixafor—Nausea—Goserelin—prostate cancer	0.00045	0.00084	CcSEcCtD
Plerixafor—Hyperhidrosis—Etoposide—prostate cancer	0.000449	0.00084	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000448	0.000837	CcSEcCtD
Plerixafor—CXCR4—Disease—GSTO1—prostate cancer	0.000447	0.00143	CbGpPWpGaD
Plerixafor—Nausea—Conjugated Estrogens—prostate cancer	0.000445	0.000832	CcSEcCtD
Plerixafor—Urticaria—Mitoxantrone—prostate cancer	0.000444	0.00083	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PTHLH—prostate cancer	0.000442	0.00141	CbGpPWpGaD
Plerixafor—Hypersensitivity—Estradiol—prostate cancer	0.000442	0.000826	CcSEcCtD
Plerixafor—Abdominal pain—Mitoxantrone—prostate cancer	0.000442	0.000825	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JUP—prostate cancer	0.000433	0.00138	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—WNT4—prostate cancer	0.000433	0.00138	CbGpPWpGaD
Plerixafor—Asthenia—Estradiol—prostate cancer	0.00043	0.000804	CcSEcCtD
Plerixafor—CXCR4—Disease—LRP2—prostate cancer	0.000429	0.00137	CbGpPWpGaD
Plerixafor—Abdominal distension—Doxorubicin—prostate cancer	0.000427	0.000798	CcSEcCtD
Plerixafor—Ill-defined disorder—Capecitabine—prostate cancer	0.000425	0.000795	CcSEcCtD
Plerixafor—Syncope—Docetaxel—prostate cancer	0.000425	0.000793	CcSEcCtD
Plerixafor—Pruritus—Estradiol—prostate cancer	0.000424	0.000793	CcSEcCtD
Plerixafor—Immune system disorder—Prednisone—prostate cancer	0.000424	0.000791	CcSEcCtD
Plerixafor—CXCR4—Disease—EIF2AK2—prostate cancer	0.000421	0.00134	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPL10—prostate cancer	0.000421	0.00134	CbGpPWpGaD
Plerixafor—CXCR4—Disease—P4HB—prostate cancer	0.000421	0.00134	CbGpPWpGaD
Plerixafor—Paraesthesia—Etoposide—prostate cancer	0.000418	0.00078	CcSEcCtD
Plerixafor—Loss of consciousness—Docetaxel—prostate cancer	0.000416	0.000777	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—ANXA1—prostate cancer	0.000416	0.00133	CbGpPWpGaD
Plerixafor—Dyspnoea—Etoposide—prostate cancer	0.000415	0.000774	CcSEcCtD
Plerixafor—Malaise—Capecitabine—prostate cancer	0.000413	0.000772	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—MC2R—prostate cancer	0.000413	0.00132	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RALBP1—prostate cancer	0.000413	0.00132	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HIST1H2BG—prostate cancer	0.000413	0.00132	CbGpPWpGaD
Plerixafor—Hypersensitivity—Mitoxantrone—prostate cancer	0.000412	0.000769	CcSEcCtD
Plerixafor—Syncope—Capecitabine—prostate cancer	0.000411	0.000768	CcSEcCtD
Plerixafor—Mental disorder—Prednisone—prostate cancer	0.000411	0.000768	CcSEcCtD
Plerixafor—Diarrhoea—Estradiol—prostate cancer	0.00041	0.000767	CcSEcCtD
Plerixafor—Erythema—Prednisone—prostate cancer	0.000408	0.000763	CcSEcCtD
Plerixafor—Arthralgia—Docetaxel—prostate cancer	0.000403	0.000753	CcSEcCtD
Plerixafor—Loss of consciousness—Capecitabine—prostate cancer	0.000403	0.000753	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PTHLH—prostate cancer	0.000402	0.00128	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Etoposide—prostate cancer	0.000401	0.00075	CcSEcCtD
Plerixafor—Asthenia—Mitoxantrone—prostate cancer	0.000401	0.000749	CcSEcCtD
Plerixafor—Fatigue—Etoposide—prostate cancer	0.000401	0.000749	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.0004	0.000748	CcSEcCtD
Plerixafor—CXCR4—Disease—HIST1H4H—prostate cancer	0.000399	0.00127	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NPPA—prostate cancer	0.000399	0.00127	CbGpPWpGaD
Plerixafor—Constipation—Etoposide—prostate cancer	0.000398	0.000743	CcSEcCtD
Plerixafor—Pain—Etoposide—prostate cancer	0.000398	0.000743	CcSEcCtD
Plerixafor—Dizziness—Estradiol—prostate cancer	0.000397	0.000741	CcSEcCtD
Plerixafor—Dry mouth—Docetaxel—prostate cancer	0.000394	0.000736	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PRKACB—prostate cancer	0.000393	0.00126	CbGpPWpGaD
Plerixafor—Arthralgia—Capecitabine—prostate cancer	0.00039	0.000729	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CALCA—prostate cancer	0.00039	0.00124	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000388	0.000724	CcSEcCtD
Plerixafor—Anaphylactic shock—Docetaxel—prostate cancer	0.000386	0.000722	CcSEcCtD
Plerixafor—Discomfort—Capecitabine—prostate cancer	0.000386	0.00072	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PPP3CA—prostate cancer	0.000383	0.00122	CbGpPWpGaD
Plerixafor—Feeling abnormal—Etoposide—prostate cancer	0.000383	0.000716	CcSEcCtD
Plerixafor—Diarrhoea—Mitoxantrone—prostate cancer	0.000382	0.000714	CcSEcCtD
Plerixafor—Dry mouth—Capecitabine—prostate cancer	0.000382	0.000713	CcSEcCtD
Plerixafor—Vomiting—Estradiol—prostate cancer	0.000381	0.000713	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL12—prostate cancer	0.000381	0.00122	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Etoposide—prostate cancer	0.00038	0.00071	CcSEcCtD
Plerixafor—Shock—Docetaxel—prostate cancer	0.00038	0.00071	CcSEcCtD
Plerixafor—Nervous system disorder—Docetaxel—prostate cancer	0.000379	0.000708	CcSEcCtD
Plerixafor—Ill-defined disorder—Prednisone—prostate cancer	0.000379	0.000708	CcSEcCtD
Plerixafor—Rash—Estradiol—prostate cancer	0.000378	0.000707	CcSEcCtD
Plerixafor—Dermatitis—Estradiol—prostate cancer	0.000378	0.000706	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—ANXA1—prostate cancer	0.000378	0.00121	CbGpPWpGaD
Plerixafor—Headache—Estradiol—prostate cancer	0.000376	0.000702	CcSEcCtD
Plerixafor—Skin disorder—Docetaxel—prostate cancer	0.000375	0.000701	CcSEcCtD
Plerixafor—Urticaria—Etoposide—prostate cancer	0.000369	0.00069	CcSEcCtD
Plerixafor—Haemoglobin—Epirubicin—prostate cancer	0.000369	0.000689	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PENK—prostate cancer	0.000368	0.00118	CbGpPWpGaD
Plerixafor—Malaise—Prednisone—prostate cancer	0.000368	0.000688	CcSEcCtD
Plerixafor—Shock—Capecitabine—prostate cancer	0.000368	0.000688	CcSEcCtD
Plerixafor—Abdominal pain—Etoposide—prostate cancer	0.000368	0.000687	CcSEcCtD
Plerixafor—Nervous system disorder—Capecitabine—prostate cancer	0.000367	0.000685	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—prostate cancer	0.000367	0.000685	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	0.000366	0.00117	CbGpPWpGaD
Plerixafor—Syncope—Prednisone—prostate cancer	0.000366	0.000684	CcSEcCtD
Plerixafor—Skin disorder—Capecitabine—prostate cancer	0.000363	0.000679	CcSEcCtD
Plerixafor—Hyperhidrosis—Capecitabine—prostate cancer	0.000362	0.000676	CcSEcCtD
Plerixafor—Connective tissue disorder—Epirubicin—prostate cancer	0.00036	0.000673	CcSEcCtD
Plerixafor—Loss of consciousness—Prednisone—prostate cancer	0.000359	0.00067	CcSEcCtD
Plerixafor—Nausea—Estradiol—prostate cancer	0.000356	0.000666	CcSEcCtD
Plerixafor—Vomiting—Mitoxantrone—prostate cancer	0.000355	0.000664	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CALCA—prostate cancer	0.000354	0.00113	CbGpPWpGaD
Plerixafor—Rash—Mitoxantrone—prostate cancer	0.000352	0.000658	CcSEcCtD
Plerixafor—Dermatitis—Mitoxantrone—prostate cancer	0.000352	0.000658	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000352	0.000658	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GHR—prostate cancer	0.000351	0.00112	CbGpPWpGaD
Plerixafor—Headache—Mitoxantrone—prostate cancer	0.00035	0.000654	CcSEcCtD
Plerixafor—Insomnia—Docetaxel—prostate cancer	0.000349	0.000653	CcSEcCtD
Plerixafor—Arthralgia—Prednisone—prostate cancer	0.000348	0.000649	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PRKCQ—prostate cancer	0.000347	0.00111	CbGpPWpGaD
Plerixafor—Paraesthesia—Docetaxel—prostate cancer	0.000347	0.000648	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCL12—prostate cancer	0.000346	0.0011	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000345	0.000645	CcSEcCtD
Plerixafor—Dyspnoea—Docetaxel—prostate cancer	0.000344	0.000644	CcSEcCtD
Plerixafor—Discomfort—Prednisone—prostate cancer	0.000343	0.000642	CcSEcCtD
Plerixafor—Hypersensitivity—Etoposide—prostate cancer	0.000343	0.00064	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—prostate cancer	0.000341	0.000637	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000341	0.000637	CcSEcCtD
Plerixafor—Dyspepsia—Docetaxel—prostate cancer	0.00034	0.000635	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—prostate cancer	0.000339	0.000634	CcSEcCtD
Plerixafor—CXCR4—Disease—B2M—prostate cancer	0.000339	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFBR1—prostate cancer	0.000339	0.00108	CbGpPWpGaD
Plerixafor—Insomnia—Capecitabine—prostate cancer	0.000338	0.000632	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—NRP1—prostate cancer	0.000337	0.00108	CbGpPWpGaD
Plerixafor—Paraesthesia—Capecitabine—prostate cancer	0.000336	0.000628	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000334	0.000623	CcSEcCtD
Plerixafor—Asthenia—Etoposide—prostate cancer	0.000334	0.000623	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—prostate cancer	0.000334	0.000623	CcSEcCtD
Plerixafor—Dyspnoea—Capecitabine—prostate cancer	0.000334	0.000623	CcSEcCtD
Plerixafor—CXCR4—Disease—AKR1C3—prostate cancer	0.000333	0.00107	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RPS19—prostate cancer	0.000333	0.00107	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Prednisone—prostate cancer	0.000333	0.000623	CcSEcCtD
Plerixafor—Fatigue—Docetaxel—prostate cancer	0.000333	0.000622	CcSEcCtD
Plerixafor—Nausea—Mitoxantrone—prostate cancer	0.000332	0.00062	CcSEcCtD
Plerixafor—CXCR4—Disease—PRKACB—prostate cancer	0.000332	0.00106	CbGpPWpGaD
Plerixafor—Immune system disorder—Epirubicin—prostate cancer	0.000331	0.000619	CcSEcCtD
Plerixafor—Pain—Docetaxel—prostate cancer	0.00033	0.000617	CcSEcCtD
Plerixafor—Constipation—Docetaxel—prostate cancer	0.00033	0.000617	CcSEcCtD
Plerixafor—Dyspepsia—Capecitabine—prostate cancer	0.000329	0.000615	CcSEcCtD
Plerixafor—Pruritus—Etoposide—prostate cancer	0.000329	0.000615	CcSEcCtD
Plerixafor—Shock—Prednisone—prostate cancer	0.000328	0.000612	CcSEcCtD
Plerixafor—Nervous system disorder—Prednisone—prostate cancer	0.000327	0.000611	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—ADRB2—prostate cancer	0.000326	0.00104	CbGpPWpGaD
Plerixafor—Skin disorder—Prednisone—prostate cancer	0.000324	0.000605	CcSEcCtD
Plerixafor—CXCR4—Disease—PPP3CA—prostate cancer	0.000323	0.00103	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000323	0.000603	CcSEcCtD
Plerixafor—Fatigue—Capecitabine—prostate cancer	0.000323	0.000603	CcSEcCtD
Plerixafor—Hyperhidrosis—Prednisone—prostate cancer	0.000322	0.000602	CcSEcCtD
Plerixafor—Mental disorder—Epirubicin—prostate cancer	0.000321	0.0006	CcSEcCtD
Plerixafor—Constipation—Capecitabine—prostate cancer	0.00032	0.000598	CcSEcCtD
Plerixafor—Pain—Capecitabine—prostate cancer	0.00032	0.000598	CcSEcCtD
Plerixafor—Erythema—Epirubicin—prostate cancer	0.000319	0.000597	CcSEcCtD
Plerixafor—Feeling abnormal—Docetaxel—prostate cancer	0.000318	0.000595	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—VAV3—prostate cancer	0.000318	0.00102	CbGpPWpGaD
Plerixafor—Diarrhoea—Etoposide—prostate cancer	0.000318	0.000594	CcSEcCtD
Plerixafor—Gastrointestinal pain—Docetaxel—prostate cancer	0.000316	0.00059	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PRKCQ—prostate cancer	0.000315	0.00101	CbGpPWpGaD
Plerixafor—Flatulence—Epirubicin—prostate cancer	0.000315	0.000588	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—VIP—prostate cancer	0.000313	0.001	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GNRH1—prostate cancer	0.000313	0.001	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PRKCZ—prostate cancer	0.000313	0.000999	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—ITPR1—prostate cancer	0.000309	0.000986	CbGpPWpGaD
Plerixafor—Feeling abnormal—Capecitabine—prostate cancer	0.000308	0.000576	CcSEcCtD
Plerixafor—Dizziness—Etoposide—prostate cancer	0.000307	0.000574	CcSEcCtD
Plerixafor—CXCR4—Disease—CALR—prostate cancer	0.000307	0.000982	CbGpPWpGaD
Plerixafor—Immune system disorder—Doxorubicin—prostate cancer	0.000307	0.000573	CcSEcCtD
Plerixafor—Gastrointestinal pain—Capecitabine—prostate cancer	0.000306	0.000571	CcSEcCtD
Plerixafor—Abdominal pain—Docetaxel—prostate cancer	0.000305	0.000571	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000304	0.000567	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—LPAR1—prostate cancer	0.000303	0.000969	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GRP—prostate cancer	0.000303	0.000969	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PARP1—prostate cancer	0.000302	0.000965	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGFR4—prostate cancer	0.000302	0.000965	CbGpPWpGaD
Plerixafor—Insomnia—Prednisone—prostate cancer	0.000301	0.000563	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PLCB2—prostate cancer	0.0003	0.000959	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LRP2—prostate cancer	0.0003	0.000959	CbGpPWpGaD
Plerixafor—Paraesthesia—Prednisone—prostate cancer	0.000299	0.000559	CcSEcCtD
Plerixafor—CXCR4—Disease—CALCA—prostate cancer	0.000298	0.000953	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—prostate cancer	0.000297	0.000556	CcSEcCtD
Plerixafor—Urticaria—Capecitabine—prostate cancer	0.000297	0.000555	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—ADRB2—prostate cancer	0.000296	0.000947	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Epirubicin—prostate cancer	0.000296	0.000554	CcSEcCtD
Plerixafor—Abdominal pain—Capecitabine—prostate cancer	0.000296	0.000552	CcSEcCtD
Plerixafor—Vomiting—Etoposide—prostate cancer	0.000296	0.000552	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—prostate cancer	0.000295	0.000552	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CX3CL1—prostate cancer	0.000294	0.000941	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—P4HB—prostate cancer	0.000294	0.000941	CbGpPWpGaD
Plerixafor—Dyspepsia—Prednisone—prostate cancer	0.000293	0.000548	CcSEcCtD
Plerixafor—Rash—Etoposide—prostate cancer	0.000293	0.000548	CcSEcCtD
Plerixafor—Dermatitis—Etoposide—prostate cancer	0.000293	0.000547	CcSEcCtD
Plerixafor—Headache—Etoposide—prostate cancer	0.000291	0.000544	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—prostate cancer	0.000291	0.000544	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—VAV3—prostate cancer	0.000289	0.000924	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HIST1H2BG—prostate cancer	0.000289	0.000923	CbGpPWpGaD
Plerixafor—Malaise—Epirubicin—prostate cancer	0.000288	0.000538	CcSEcCtD
Plerixafor—Fatigue—Prednisone—prostate cancer	0.000287	0.000537	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PDE4D—prostate cancer	0.000286	0.000915	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GRB7—prostate cancer	0.000286	0.000915	CbGpPWpGaD
Plerixafor—Syncope—Epirubicin—prostate cancer	0.000286	0.000535	CcSEcCtD
Plerixafor—CXCR4—Disease—HSPA1A—prostate cancer	0.000286	0.000914	CbGpPWpGaD
Plerixafor—Constipation—Prednisone—prostate cancer	0.000285	0.000532	CcSEcCtD
Plerixafor—Hypersensitivity—Docetaxel—prostate cancer	0.000285	0.000532	CcSEcCtD
Plerixafor—Loss of consciousness—Epirubicin—prostate cancer	0.000281	0.000524	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—ITPR1—prostate cancer	0.00028	0.000896	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HIST1H4H—prostate cancer	0.000279	0.000892	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—prostate cancer	0.000279	0.000891	CbGpPWpGaD
Plerixafor—Asthenia—Docetaxel—prostate cancer	0.000277	0.000518	CcSEcCtD
Plerixafor—Nausea—Etoposide—prostate cancer	0.000276	0.000516	CcSEcCtD
Plerixafor—Hypersensitivity—Capecitabine—prostate cancer	0.000276	0.000515	CcSEcCtD
Plerixafor—Feeling abnormal—Prednisone—prostate cancer	0.000275	0.000513	CcSEcCtD
Plerixafor—CXCR4—Disease—CASP9—prostate cancer	0.000275	0.000877	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Doxorubicin—prostate cancer	0.000274	0.000512	CcSEcCtD
Plerixafor—Pruritus—Docetaxel—prostate cancer	0.000273	0.000511	CcSEcCtD
Plerixafor—Gastrointestinal pain—Prednisone—prostate cancer	0.000273	0.000509	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GNG5—prostate cancer	0.000272	0.000871	CbGpPWpGaD
Plerixafor—Arthralgia—Epirubicin—prostate cancer	0.000272	0.000508	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.00027	0.000504	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—prostate cancer	0.000269	0.000502	CcSEcCtD
Plerixafor—Asthenia—Capecitabine—prostate cancer	0.000268	0.000501	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—prostate cancer	0.000266	0.000498	CcSEcCtD
Plerixafor—CXCR4—Disease—PRKCQ—prostate cancer	0.000266	0.00085	CbGpPWpGaD
Plerixafor—Dry mouth—Epirubicin—prostate cancer	0.000266	0.000497	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—prostate cancer	0.000265	0.000495	CcSEcCtD
Plerixafor—Urticaria—Prednisone—prostate cancer	0.000265	0.000495	CcSEcCtD
Plerixafor—Pruritus—Capecitabine—prostate cancer	0.000265	0.000494	CcSEcCtD
Plerixafor—Diarrhoea—Docetaxel—prostate cancer	0.000264	0.000494	CcSEcCtD
Plerixafor—Abdominal pain—Prednisone—prostate cancer	0.000263	0.000492	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—prostate cancer	0.000261	0.000487	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—prostate cancer	0.00026	0.000485	CcSEcCtD
Plerixafor—Shock—Epirubicin—prostate cancer	0.000256	0.000479	CcSEcCtD
Plerixafor—Diarrhoea—Capecitabine—prostate cancer	0.000256	0.000478	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—prostate cancer	0.000256	0.000477	CcSEcCtD
Plerixafor—Dizziness—Docetaxel—prostate cancer	0.000256	0.000477	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—prostate cancer	0.000253	0.000473	CcSEcCtD
Plerixafor—CXCR4—Disease—FGF10—prostate cancer	0.000253	0.000807	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Epirubicin—prostate cancer	0.000252	0.000471	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—prostate cancer	0.000252	0.00047	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.00025	0.000467	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—prostate cancer	0.000249	0.000464	CcSEcCtD
Plerixafor—Dizziness—Capecitabine—prostate cancer	0.000247	0.000462	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—prostate cancer	0.000246	0.00046	CcSEcCtD
Plerixafor—Vomiting—Docetaxel—prostate cancer	0.000246	0.000459	CcSEcCtD
Plerixafor—Hypersensitivity—Prednisone—prostate cancer	0.000246	0.000459	CcSEcCtD
Plerixafor—Rash—Docetaxel—prostate cancer	0.000244	0.000455	CcSEcCtD
Plerixafor—Dermatitis—Docetaxel—prostate cancer	0.000243	0.000455	CcSEcCtD
Plerixafor—Headache—Docetaxel—prostate cancer	0.000242	0.000452	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—prostate cancer	0.000241	0.000451	CcSEcCtD
Plerixafor—CXCR4—Disease—TGFBR2—prostate cancer	0.00024	0.000768	CbGpPWpGaD
Plerixafor—Asthenia—Prednisone—prostate cancer	0.000239	0.000447	CcSEcCtD
Plerixafor—Vomiting—Capecitabine—prostate cancer	0.000238	0.000444	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000237	0.000444	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TGFBR1—prostate cancer	0.000237	0.000758	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTHLH—prostate cancer	0.000237	0.000758	CbGpPWpGaD
Plerixafor—Shock—Doxorubicin—prostate cancer	0.000237	0.000443	CcSEcCtD
Plerixafor—CXCR4—Disease—ITPR1—prostate cancer	0.000237	0.000756	CbGpPWpGaD
Plerixafor—Nervous system disorder—Doxorubicin—prostate cancer	0.000236	0.000442	CcSEcCtD
Plerixafor—Rash—Capecitabine—prostate cancer	0.000236	0.000441	CcSEcCtD
Plerixafor—Pruritus—Prednisone—prostate cancer	0.000236	0.00044	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—prostate cancer	0.000236	0.00044	CcSEcCtD
Plerixafor—Dermatitis—Capecitabine—prostate cancer	0.000236	0.00044	CcSEcCtD
Plerixafor—Headache—Capecitabine—prostate cancer	0.000234	0.000438	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—prostate cancer	0.000234	0.000438	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—prostate cancer	0.000234	0.000437	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AKR1C3—prostate cancer	0.000234	0.000746	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Doxorubicin—prostate cancer	0.000233	0.000436	CcSEcCtD
Plerixafor—Dyspnoea—Epirubicin—prostate cancer	0.000232	0.000434	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRKACB—prostate cancer	0.000232	0.000742	CbGpPWpGaD
Plerixafor—Nausea—Docetaxel—prostate cancer	0.00023	0.000429	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—prostate cancer	0.000229	0.000429	CcSEcCtD
Plerixafor—Diarrhoea—Prednisone—prostate cancer	0.000228	0.000426	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PPP3CA—prostate cancer	0.000226	0.000723	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—THBS1—prostate cancer	0.000226	0.000723	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000225	0.00042	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—prostate cancer	0.000225	0.00042	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ANXA1—prostate cancer	0.000223	0.000713	CbGpPWpGaD
Plerixafor—Constipation—Epirubicin—prostate cancer	0.000223	0.000416	CcSEcCtD
Plerixafor—Pain—Epirubicin—prostate cancer	0.000223	0.000416	CcSEcCtD
Plerixafor—Nausea—Capecitabine—prostate cancer	0.000222	0.000415	CcSEcCtD
Plerixafor—Dizziness—Prednisone—prostate cancer	0.00022	0.000412	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.00022	0.00041	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRKCZ—prostate cancer	0.000219	0.0007	CbGpPWpGaD
Plerixafor—Insomnia—Doxorubicin—prostate cancer	0.000218	0.000407	CcSEcCtD
Plerixafor—CXCR4—Disease—LPL—prostate cancer	0.000217	0.000693	CbGpPWpGaD
Plerixafor—Paraesthesia—Doxorubicin—prostate cancer	0.000217	0.000405	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—prostate cancer	0.000215	0.000402	CcSEcCtD
Plerixafor—CXCR4—Disease—PDGFRB—prostate cancer	0.000215	0.000687	CbGpPWpGaD
Plerixafor—Feeling abnormal—Epirubicin—prostate cancer	0.000215	0.000401	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—prostate cancer	0.000214	0.000684	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Epirubicin—prostate cancer	0.000213	0.000398	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—prostate cancer	0.000212	0.000397	CcSEcCtD
Plerixafor—Vomiting—Prednisone—prostate cancer	0.000212	0.000396	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FGFR4—prostate cancer	0.000212	0.000676	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PARP1—prostate cancer	0.000212	0.000676	CbGpPWpGaD
Plerixafor—Rash—Prednisone—prostate cancer	0.00021	0.000393	CcSEcCtD
Plerixafor—Dermatitis—Prednisone—prostate cancer	0.00021	0.000392	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CALCA—prostate cancer	0.000209	0.000668	CbGpPWpGaD
Plerixafor—Headache—Prednisone—prostate cancer	0.000209	0.00039	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000208	0.000389	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—prostate cancer	0.000208	0.000388	CcSEcCtD
Plerixafor—CXCR4—Disease—ERCC2—prostate cancer	0.000208	0.000664	CbGpPWpGaD
Plerixafor—Urticaria—Epirubicin—prostate cancer	0.000207	0.000387	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—prostate cancer	0.000206	0.000385	CcSEcCtD
Plerixafor—Pain—Doxorubicin—prostate cancer	0.000206	0.000385	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—prostate cancer	0.000206	0.000385	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CXCL12—prostate cancer	0.000204	0.000652	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB3—prostate cancer	0.000203	0.000649	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGFR2—prostate cancer	0.000203	0.000648	CbGpPWpGaD
Plerixafor—Feeling abnormal—Doxorubicin—prostate cancer	0.000199	0.000371	CcSEcCtD
Plerixafor—Nausea—Prednisone—prostate cancer	0.000198	0.00037	CcSEcCtD
Plerixafor—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000197	0.000368	CcSEcCtD
Plerixafor—CXCR4—Disease—MTHFR—prostate cancer	0.000195	0.000624	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TERT—prostate cancer	0.000195	0.000622	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—prostate cancer	0.000194	0.000621	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP9—prostate cancer	0.000192	0.000614	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—prostate cancer	0.000192	0.000359	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—prostate cancer	0.000192	0.000358	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—prostate cancer	0.000191	0.000356	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—prostate cancer	0.000188	0.000601	CbGpPWpGaD
Plerixafor—Asthenia—Epirubicin—prostate cancer	0.000187	0.000349	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRKCQ—prostate cancer	0.000186	0.000595	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NGFR—prostate cancer	0.000186	0.000595	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HIF1A—prostate cancer	0.000186	0.000595	CbGpPWpGaD
Plerixafor—Pruritus—Epirubicin—prostate cancer	0.000184	0.000344	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—MAP3K7—prostate cancer	0.000184	0.000588	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CAV1—prostate cancer	0.00018	0.000575	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—prostate cancer	0.000178	0.000333	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—prostate cancer	0.000178	0.000332	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FGF10—prostate cancer	0.000177	0.000565	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ADRB2—prostate cancer	0.000175	0.000559	CbGpPWpGaD
Plerixafor—Asthenia—Doxorubicin—prostate cancer	0.000173	0.000323	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—JAK2—prostate cancer	0.000173	0.000552	CbGpPWpGaD
Plerixafor—Dizziness—Epirubicin—prostate cancer	0.000172	0.000322	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—MAP2K1—prostate cancer	0.000172	0.00055	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—prostate cancer	0.000171	0.000546	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VAV3—prostate cancer	0.000171	0.000546	CbGpPWpGaD
Plerixafor—Pruritus—Doxorubicin—prostate cancer	0.000171	0.000319	CcSEcCtD
Plerixafor—CXCR4—Disease—BAD—prostate cancer	0.000169	0.000541	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFBR2—prostate cancer	0.000168	0.000538	CbGpPWpGaD
Plerixafor—Vomiting—Epirubicin—prostate cancer	0.000166	0.00031	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ITPR1—prostate cancer	0.000166	0.000529	CbGpPWpGaD
Plerixafor—Diarrhoea—Doxorubicin—prostate cancer	0.000165	0.000308	CcSEcCtD
Plerixafor—Rash—Epirubicin—prostate cancer	0.000164	0.000307	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—prostate cancer	0.000164	0.000307	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—prostate cancer	0.000164	0.000524	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APC—prostate cancer	0.000164	0.000524	CbGpPWpGaD
Plerixafor—Headache—Epirubicin—prostate cancer	0.000163	0.000305	CcSEcCtD
Plerixafor—CXCR4—Disease—EGF—prostate cancer	0.000162	0.000518	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IRS1—prostate cancer	0.000162	0.000518	CbGpPWpGaD
Plerixafor—Dizziness—Doxorubicin—prostate cancer	0.000159	0.000298	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—IGF1R—prostate cancer	0.000158	0.000506	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—prostate cancer	0.000158	0.000504	CbGpPWpGaD
Plerixafor—CXCR4—Disease—GSK3B—prostate cancer	0.000157	0.000503	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—JAK2—prostate cancer	0.000157	0.000501	CbGpPWpGaD
Plerixafor—CXCR4—Disease—INS—prostate cancer	0.000155	0.000496	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—prostate cancer	0.000155	0.000289	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—prostate cancer	0.000153	0.000286	CcSEcCtD
Plerixafor—CXCR4—Disease—CREBBP—prostate cancer	0.000152	0.000486	CbGpPWpGaD
Plerixafor—Rash—Doxorubicin—prostate cancer	0.000152	0.000284	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—prostate cancer	0.000152	0.000284	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—LPL—prostate cancer	0.000152	0.000485	CbGpPWpGaD
Plerixafor—Headache—Doxorubicin—prostate cancer	0.000151	0.000282	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—prostate cancer	0.000151	0.000481	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PDGFRB—prostate cancer	0.00015	0.000481	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—prostate cancer	0.000149	0.000476	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ITGB3—prostate cancer	0.000147	0.000469	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAP2K1—prostate cancer	0.000145	0.000464	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CD—prostate cancer	0.000144	0.000461	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—prostate cancer	0.000143	0.000268	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—prostate cancer	0.000143	0.000457	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SERPINE1—prostate cancer	0.000143	0.000456	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB3—prostate cancer	0.000142	0.000454	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGFR2—prostate cancer	0.000142	0.000454	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGF2—prostate cancer	0.000138	0.000441	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL2—prostate cancer	0.000137	0.000437	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—prostate cancer	0.000136	0.000436	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOS3—prostate cancer	0.000136	0.000435	CbGpPWpGaD
Plerixafor—CXCR4—Disease—JAK2—prostate cancer	0.000132	0.000423	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HIF1A—prostate cancer	0.00013	0.000417	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MDM2—prostate cancer	0.000129	0.000413	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—prostate cancer	0.000127	0.000407	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LEP—prostate cancer	0.000127	0.000407	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CAV1—prostate cancer	0.000126	0.000403	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CB—prostate cancer	0.000126	0.000402	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KDR—prostate cancer	0.000125	0.000398	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—prostate cancer	0.000125	0.000398	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ESR1—prostate cancer	0.000122	0.000388	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BAD—prostate cancer	0.000119	0.000379	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—prostate cancer	0.000118	0.000377	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APC—prostate cancer	0.000115	0.000367	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—prostate cancer	0.000115	0.000367	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGF—prostate cancer	0.000114	0.000363	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IRS1—prostate cancer	0.000114	0.000363	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—prostate cancer	0.000111	0.000356	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GSK3B—prostate cancer	0.00011	0.000352	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1A—prostate cancer	0.000109	0.000348	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—INS—prostate cancer	0.000109	0.000347	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—prostate cancer	0.000109	0.000347	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CREBBP—prostate cancer	0.000106	0.00034	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1—prostate cancer	0.000105	0.000336	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—prostate cancer	0.000105	0.000334	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EP300—prostate cancer	0.000104	0.000331	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAP2K1—prostate cancer	0.000102	0.000325	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—prostate cancer	0.000101	0.000323	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SRC—prostate cancer	0.000101	0.000322	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—prostate cancer	0.0001	0.00032	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SERPINE1—prostate cancer	9.99e-05	0.000319	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—prostate cancer	9.89e-05	0.000316	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—prostate cancer	9.71e-05	0.00031	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGF2—prostate cancer	9.67e-05	0.000309	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOS3—prostate cancer	9.54e-05	0.000305	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JAK2—prostate cancer	9.27e-05	0.000296	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—prostate cancer	9.08e-05	0.00029	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MDM2—prostate cancer	9.05e-05	0.000289	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—prostate cancer	9.03e-05	0.000288	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFB1—prostate cancer	9e-05	0.000288	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—prostate cancer	8.92e-05	0.000285	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—prostate cancer	8.83e-05	0.000282	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—prostate cancer	8.8e-05	0.000281	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—prostate cancer	8.46e-05	0.00027	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—prostate cancer	8.34e-05	0.000266	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—prostate cancer	8.26e-05	0.000264	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—prostate cancer	8.17e-05	0.000261	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—prostate cancer	8.1e-05	0.000259	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—prostate cancer	8.08e-05	0.000258	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—prostate cancer	8.04e-05	0.000257	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—prostate cancer	7.88e-05	0.000252	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—prostate cancer	7.8e-05	0.000249	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—prostate cancer	7.66e-05	0.000245	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—prostate cancer	7.65e-05	0.000244	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1A—prostate cancer	7.62e-05	0.000244	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—prostate cancer	7.61e-05	0.000243	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—prostate cancer	7.42e-05	0.000237	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EP300—prostate cancer	7.25e-05	0.000232	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SRC—prostate cancer	7.05e-05	0.000225	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—prostate cancer	6.87e-05	0.000219	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—prostate cancer	6.8e-05	0.000217	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—prostate cancer	6.78e-05	0.000217	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—prostate cancer	6.32e-05	0.000202	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFB1—prostate cancer	6.31e-05	0.000201	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—prostate cancer	6.26e-05	0.0002	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—prostate cancer	6.18e-05	0.000198	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—prostate cancer	5.84e-05	0.000187	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—prostate cancer	5.37e-05	0.000171	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—prostate cancer	5.19e-05	0.000166	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—prostate cancer	4.75e-05	0.000152	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—prostate cancer	4.38e-05	0.00014	CbGpPWpGaD
